$4.04
+0.03 (+0.75%)
Open$4.03
Previous Close$4.01
Day High$4.05
Day Low$3.89
52W High$5.08
52W Low$1.29
Volume—
Avg Volume567.0K
Market Cap259.34M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+985.4% upside
Current
$4.04
$4.04
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 151.96M | 152.77M | 19.43M |
| Net Income | -75,843,385 | -68,622,747 | 4.04M |
| Profit Margin | -49.9% | -47.4% | 20.8% |
| EBITDA | -66,747,314 | -63,747,811 | 6.14M |
| Free Cash Flow | — | — | 2.37M |
| Rev Growth | -0.5% | -0.5% | +14.5% |
| Debt/Equity | 1.26 | 1.26 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |